Blood Glucose Monitoring Test Strips Improved
|
By LabMedica International staff writers Posted on 24 Nov 2009 |
|
A new and improved blood glucose monitoring test strip has been launched.
The Assure Pro blood glucose monitoring system is designed for long-term care and multiresident use settings. Feature loaded, the Assure Pro meter helps facilities meet state regulatory standards and provide better resident care. The strips require 50% less blood, reducing the sample size from 1 µL to only 0.5 µL. All Assure blood glucose-monitoring systems utilize glucose oxidase (GO) strip chemistry, which is not affected by interferences that cause testing errors in other common test strips.
Assure Blood Glucose Meters are backed by the Assure Brilliance program--a comprehensive service program for diabetes management in long-term care (LTC). Assure Brilliance provides customer service, on-site training, Quality Assurance/Quality Control (QA/QC) guidance, diabetes F-Tag advice for LTC, a quarterly newsletter, online CE programs, and more to help facilities manage complex diabetes care in their facilities.
Arkray Inc. (Edina, MN, USA), a manufacturer of diabetes self-monitoring systems, launched the new and improved Blood Glucose Monitoring Test Strip. The company manufactures and distributes cost-effective products that are simple, convenient, and easy-to-use, including blood glucose meters, test strips, safety lancets, and urine chemistry.
Related Links:
Arkray Inc.
The Assure Pro blood glucose monitoring system is designed for long-term care and multiresident use settings. Feature loaded, the Assure Pro meter helps facilities meet state regulatory standards and provide better resident care. The strips require 50% less blood, reducing the sample size from 1 µL to only 0.5 µL. All Assure blood glucose-monitoring systems utilize glucose oxidase (GO) strip chemistry, which is not affected by interferences that cause testing errors in other common test strips.
Assure Blood Glucose Meters are backed by the Assure Brilliance program--a comprehensive service program for diabetes management in long-term care (LTC). Assure Brilliance provides customer service, on-site training, Quality Assurance/Quality Control (QA/QC) guidance, diabetes F-Tag advice for LTC, a quarterly newsletter, online CE programs, and more to help facilities manage complex diabetes care in their facilities.
Arkray Inc. (Edina, MN, USA), a manufacturer of diabetes self-monitoring systems, launched the new and improved Blood Glucose Monitoring Test Strip. The company manufactures and distributes cost-effective products that are simple, convenient, and easy-to-use, including blood glucose meters, test strips, safety lancets, and urine chemistry.
Related Links:
Arkray Inc.
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Urinalysis Solution
UN-9000
Latest Clinical Chem. News
- New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
- Multi-Protein Blood Test Improves Staging of Alzheimer’s Disease
- Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
- AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer
- Compact Prenatal Screening System Expands Access to Preeclampsia Testing
- Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
- Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
- Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
Channels
Molecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read more
Microbiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read more
Pathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Technology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more